Ti and Zr Benzyl Complexes
Organometallics, Vol. 25, No. 2, 2006 465
29 °C): δC 24.18 (CH3, i-Pr), 29.16 (t, CH, i-Pr), 31.36 (t, JPC
)
mixture was vigorously shaken. Owing to high thermal instability
and very high air and moisture sensitivity, this substance could not
be isolated, and the resulting red solution was investigated only by
6.5 Hz, CH3, t-Bu), 51.60 (t, JPC ) 14.5 Hz, C, t-Bu), 68.64 (CH2-
Ph), 122.24 (Ph), 123.98 (Ar), 126.89 (Ph), 129.00 (Ph), 136.37
(Ar), 140.96 (Ar), 144.43 (Ar), 146.88 (Ph). 31P{1H} NMR (202
MHz, C6D6, 21 °C): δP 115.68 (s). MS (EI): m/z (%) 781 (2, M+),
695 (7, M+ - CH2Ph), 604 (10, M+ - 2 CH2Ph), 556 (30, ligand).
1
NMR methods. H NMR (500 MHz, CD2Cl2, 27 °C): δH 1.27-
1.64 (m, 36H, t-Bu), 2.79 (br s, 2H, PhCH2B), 2.89 (s, 2H, PhCH2-
Ti), 6.73 (d, J ) 7.3 Hz, 2H, PhCH2B), 6.76 (t, J ) 7.3 Hz, 1H,
PhCH2B), 6.85 (t, J ) 7.3 Hz, 2H, PhCH2B), 7.1-7.5 (m, 5H,
PhCH2Ti). 31P{1H} NMR (202 MHz, CD2Cl2, 27 °C): δP 64.46
(s). 19F NMR (470 MHz, CD2Cl2, 27 °C): δF -130.84 (d), -164.51
(t), -167.30 (d).
[(2,5-t-Bu2C6H3N)(t-BuNP)]2Zr(CH2Ph)Cl (12). [(2,5-t-Bu2C6-
H3N)(t-BuNP)]2ZrCl2 (10) (0.62 g, 0.8 mmol) in Et2O (30 mL) was
treated with PhCH2MgCl in THF (2 M, 1.0 mL, 2.0 mmol), as
described above, and separation of the product was carried out as
reported for [(t-BuN)(t-BuNP)]2Ti(CH2Ph)Cl. Complex 12 was
isolated as a yellow-brown solid (0.52 g; 78.5%) (C43H67N4P2ZrCl
calcd C, 62.33; H, 8.15; N, 6.76, found C, 61.89; H, 8.52; N, 7.05).
1H NMR (200 MHz, CD2Cl2, 29 °C): δH 1.25 (s, 18H, 2-t-BuAr),
1.26 (s, 18H, 5-t-BuAr), 1.42 (s, 18H, t-Bu), 3.24 (s, 2H, CH2Ph),
6.74 (dd, 2H, 1J ) 6.2 Hz, 2J ) 2.2 Hz, 4-H-Ar); 6.60-7.30 (5H,
Reaction of [(2,5-t-Bu2C6H3N)(t-BuNP)]2Ti(CH2Ph)2 with
B(C6F5)3. In a glovebox [(2,5-t-Bu2C6H3N)(t-BuNP)]2Ti(CH2Ph)2
(7) (89 mg, 106 µmol) and B(C6F5)3 (54 mg, 106 µmol) were mixed
in a NMR tube and dissolved in CD2Cl2, as described for [(t-BuN)-
(t-BuNP)]2Ti(CH2Ph)2 + B(C6F5)3. Owing to high thermal instabil-
ity and very high air and moisture sensitivity, the substance could
not be isolated, and the resulting red solution was investigated only
1
2
Ph), 7.16 (2H, 3-H-Ar), 7.69 (dd, 2H, J ) 3.3 Hz, J ) 2.2 Hz,
6-H-Ar). 13C{1H} NMR (50.3 MHz, CD2Cl2, 29 °C): δC 30.85
(CH3, 5-t-BuAr), 31.15 (t, JPC ) 6.5 Hz, CH3, t-Bu), 31.34 (CH3,
2-t-BuAr), 34.00 (C, 5-t-BuAr), 34.49 (C, 2-t-BuAr), 51.67 (t, JPC
) 13.73 Hz, C, t-Bu), 72.34 (CH2Ph), 113.47 (Ar), 114.16 (Ar),
116.51 (Ar), 126.66 (Ph), 128.52 (Ph), 128.70 (Ph), 131.27 (Ar),
141.9 (d, J ) 9.9 Hz, Ar), 142.18 (Ph), 149.98 (t, J ) 1.2 Hz, Ar).
31P{1H} NMR (162 MHz, CD2Cl2, 31 °C): δP 97.89 (s). MS(EI):
m/z (%) 829 (1, M+), 737 (3, M+ - CH2Ph), 612 (80, ligand).
1
by NMR methods. H NMR (500 MHz, CD2Cl2, 27 °C): δH 1.29
(s, 36H, t-BuAr), 1.46 (s, 18H, t-Bu), 2.82 (br s, 2H, PhCH2B),
2.90 (s, 2H, CH2PhTi), 6.74 (d, J ) 7.3 Hz, 2H, PhCH2B), 6.77
(br s, 1H, PhCH2B), 6.86 (t, J ) 7.3 Hz, 2H, PhCH2B), 7.10-7.28
(m, 9H, Ar and CH2PhTi), 7.74 (s, 2H, 6-H-Ar). 31P{1H} NMR
(202 MHz, CD2Cl2, 27 °C): δP 99.00 (s). 19F NMR (470 MHz,
CD2Cl2, 27 °C): δF -130.84 (d), -164.45 (t), -167.26 (d).
Reaction of [(t-BuN)(t-BuNP)]2Zr(CH2Ph)2 with B(C6F5)3. In
a glovebox [(t-BuN)(t-BuNP)]2Zr(CH2Ph)2 (14) (60 mg, 106 µmol)
and B(C6F5)3 (54 mg, 106 µmol) were mixed in a NMR tube and
dissolved in CD2Cl2 or C6D5Br, as described for [(t-BuN)(t-
BuNP)]2Ti(CH2Ph)2 + B(C6F5)3. Owing to high thermal instability
and very high air and moisture sensitivity, the substance could not
be isolated, and the resulting orange solution was investigated only
[(2,6-i-Pr2C6H3N)(t-BuNP)]2Zr(CH2Ph)Cl (13). [(2,6-i-Pr2C6-
H3N)(t-BuNP)]2ZrCl2 (11) (1.0 g, 1.4 mmol) in Et2O (30 mL) was
treated with PhCH2MgCl in THF (2 M, 1.4 mL, 2.8 mmol), as
described above, and separation of the product was carried out as
reported for [(t-BuN)(t-BuNP)]2Ti(CH2Ph)Cl. Complex 13 was
isolated as an orange oil (0.80 g; 74.1%) (C39H59N4P2ZrCl calcd
1
by NMR methods. H NMR (500 MHz, CD2Cl2, 27 °C): δH 1.36
1
C, 60.63; H, 7.70; N, 7.25; found C, 61.09; H, 8.06; N, 6.96). H
(s, 18H, t-Bu), 1.39 (s, 18H, t-Bu), 2.79 (br s, 2H, PhCH2B), 3.10
(s, 2H, PhCH2Zr), 6.72 (d, J ) 7.8 Hz, PhCH2B), 6.76 (t, J ) 7.3
Hz, PhCH2B), 6.84 (t, J ) 7.3 Hz, PhCH2B), 7.05-7.25 (m, PhCH2-
Zr and PhCH3). 1H NMR (200 MHz, C6D5Br, 27 °C): δH 1.20 (s,
18H, t-Bu), 1.32 (s, 18H, t-Bu), 3.10 (s, 2H, PhCH2Zr), 3.29 (br s,
2H, PhCH2B), 6.88-7.20 ppm (m, 10H, PhCH2B and PhCH2Zr).
13C{1H} NMR (50.3 MHz, CD2Cl2, 29 °C): δC 28.96 (m, BCH2-
NMR (200 MHz, CD2Cl2, 29 °C): δH 1.16 (s, 18H, t-Bu), 1.24 (d,
24H, CH3, i-Pr), 2.46 (d, 2H, CH2Ph), 3.63 (m, 4H, CH, i-Pr), 6.70-
7.30 (11H, H-Ar and Ph). 13C{1H} NMR (50.3 MHz, CD2Cl2, 29
°C): δC 24.03 (CH3, i-Pr), 29.03 (t, CH, i-Pr), 31.25 (t, JPC ) 6.5
Hz, CH3, t-Bu), 51.58 (t, JPC ) 14.5 Hz, C, t-Bu), 72.41 (CH2Ph),
121.72 (Ph), 123.71 (Ar), 128.55 (Ph), 128.72 (Ph), 136.41 (Ar),
141.11 (Ar), 144.44 (Ar), 146.38 (Ph). 31P{1H} NMR (162 MHz,
CD2Cl2, 27 °C): δP 113.74 (s). MS (EI): m/z (%) 772 (1, M+),
736 (3, M+ - Cl), 556 (30, ligand).
[(t-BuN)(t-BuNP)]2Zr(CH2Ph)2 (14). [(t-BuN)(t-BuNP)]2ZrCl2
(9) (1.0 g, 2.0 mmol) in Et2O (30 mL) was treated with PhCH2-
MgCl in THF (2 M, 2.0 mL, 4.0 mmol), as described above, and
separation of the product was carried out as reported for [(t-BuN)-
(t-BuNP)]2Ti(CH2Ph)Cl. Complex 14 was isolated as a yellow
crystalline solid (1.09 g; 89.3%) (C30H50N4P2Zr calcd C, 58.12; H,
8.13; found C, 58.41; H, 7.89). 1H NMR (200 MHz, C6D6, 29 °C):
δH 1.27 (s, 18H, t-Bu, P2N2 cycle), 1.46 (s, 18H, t-Bu), 2.78 (s,
4H, CH2Ph), 6.76 (t, JHH ) 7.33 Hz, 2H, Ph), 6.91 (d, JHH ) 7.0
Hz, 4H, Ph), 7.06 (t, JHH ) 7.33 Hz, 4H, Ph). 1H NMR (500 MHz,
CD2Cl2, 29 °C): δH 1.21 (s, 18H, t-Bu, P2N2 cycle), 1.33 (s, 18H,
t-Bu), 2.45 (s, 4H, CH2Ph), 6.76 (t, JHH ) 7.33 Hz, 2H, Ph), 6.89
(d, JHH ) 7.32 Hz, 4H, Ph), 7.07 (t, JHH ) 7.33 Hz, 4H, Ph). 13C-
{1H} NMR (50.3 MHz, C6D6, 29 °C): δC 30.00 (t, JPC ) 6.5 Hz,
CH3, t-Bu, P2N2 cycle), 34.10 (d, JPC ) 9.2 Hz, CH3, t-Bu), 54.41
(t, JPC ) 13.7 Hz, C, t-Bu, P2N2 cycle), 59.41 (d, JPC ) 17.2 Hz,
C, t-Bu), 76.49 (CH2Ph), 121.91 (Ph), 126.93 (Ph), 128.80 (Ph),
146.14 (ipso-C, Ph). 31P{1H} NMR (162 MHz, CD2Cl2, 27 °C):
δP 106.11 (s). MS(EI): m/z (%) 527 (80, M+ - CH2Ph), 349 (90,
ligand).
Ph); 29.93 (t, JPC ) 6 Hz, CH3, t-Bu, P2N2 cycle), 33.40 (d, JPC
)
8.4 Hz, CH3, t-Bu), 55.32 (t, JPC ) 13.7 Hz, C, t-Bu, P2N2 cycle),
57.60 (d, JPC ) 15.6 Hz, C, t-Bu), 71.6 (ZrCH2Ph), 122.63 (ZrCH2-
Ph), 125.72 (BCH2Ph), 127.0 (BCH2Ph), 128.86 (ZrCH2Ph), 128.95
(BCH2Ph), 129.46 (ZrCH2Ph), 132.66 (ipso-C, BCH2Ph), 135.0 (m,
C6F5), 139.7 (m, C6F5), 146.22 (m, C6F5), 148.95 (ipso-C, ZrCH2-
Ph), 151.2 (m, C6F5). 13C{1H} NMR (50.3 MHz, C6D5Br, 29 °C):
δC 33.6 (t, CH3, t-Bu, P2N2 cycle), 34.40 (d, CH3, t-Bu), 38.39 (m,
BCH2Ph), 54.76 (t, JPC ) 14.8 Hz, C, t-Bu, P2N2 cycle), 59.36 (d,
JPC ) 20.5 Hz, C, t-Bu), 71.04 (ZrCH2Ph), 122.25 (BCH2Ph),
125.58 (ZrCH2Ph), 128.64 (BCH2Ph), 128.98 (BCH2Ph), 129.2
(ZrCH2Ph), 129.47 (ZrCH2Ph), 134.1 (m, C6F5), 137.22 (ipso-C,
BCH2Ph), 139.1 (m, C6F5), 141.59 (ipso-C, ZrCH2Ph), 146.2 (m,
C6F5), 151.1 (m, C6F5). 31P{1H} NMR (202 MHz, CD2Cl2, 27 °C):
δP 108.52 (s, complex 14, traces), 103.66 (s, cation). 31P{1H} NMR
(202 MHz, C6D5Br, 27 °C): δP 106.6 (s, complex 14, traces), 102.1
(s, cation). 19F NMR (470 MHz, CD2Cl2, 27 °C): δF -127.74 (d,
B(C6F5)3), -130.89 (d, PhCH2B(C6F5)3-), -143.38 (s, B(C6F5)3),
-160.57 (q, B(C6F5)3), -164.64 (t, PhCH2B(C6F5)3-), -167.40 (d,
PhCH2B(C6F5)3-).
{[(t-BuN)(t-BuNP)]2Zr(CH2Ph)(Et2O)}+[PhCH2B(C6F5)3]- (15).
In a glovebox [(t-BuN)(t-BuNP)]2Zr(CH2Ph)2 (14) (120 mg, 212
µmol) and B(C6F5)3 (108 mg, 212 µmol) were mixed in a test tube
and dissolved in Et2O. The reaction occurred immediately and oily
material started to precipitate. The reaction mixture was separated
from that precipitation and transferred into another test tube. The
target product was slowly precipitated by addition of a hexane layer.
All solvents were removed with a syringe, and the yellow oily
Generation of Cationic Species. Reaction of [(t-BuN)(t-
BuNP)]2Ti(CH2Ph)2 with B(C6F5)3. In a glovebox a NMR tube
was charged with [(t-BuN)(t-BuNP)]2Ti(CH2Ph)2 (5) (55 mg, 106
µmol) and B(C6F5)3 (54 mg, 106 µmol), after which 0.6 mL of
CD2Cl2 was added via a syringe at room temperature and the